Comparative Pharmacology
Head-to-head clinical analysis: TIAMATE versus ZYBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIAMATE versus ZYBAN.
TIAMATE vs ZYBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiamate is a combination of tiamulin (a pleuromutilin antibiotic) and valnemulin (a pleuromutilin antibiotic). Tiamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically at the peptidyl transferase center, preventing peptide bond formation. Valnemulin similarly binds to the 50S subunit and inhibits protein synthesis.
Bupropion is a selective dopamine and norepinephrine reuptake inhibitor with weak inhibition of serotonin reuptake. Its mechanism in smoking cessation and depression is not fully understood.
250 mg orally twice daily
150 mg orally once daily for 3 days, then increase to 150 mg twice daily for a total treatment duration of 7-12 weeks.
None Documented
None Documented
Terminal half-life 2–4 hours; dose adjustment needed in renal impairment (CrCl <30 mL/min)
The terminal elimination half-life of bupropion is approximately 21 hours (range 18-24 h), while its active metabolites have longer half-lives: hydroxybupropion ~20 h, threohydrobupropion ~37 h, erythrohydrobupropion ~33 h. Steady state is achieved within 8 days.
Primarily renal (70–80% as unchanged drug); biliary/fecal (20–30%)
Renal excretion accounts for approximately 87% of an oral dose, with 42% as unchanged bupropion and its active metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion). Fecal excretion is minimal at <10%.
Category C
Category C
Antidepressant
Antidepressant, Smoking Cessation Aid